Literature DB >> 25683728

FOXP3 suppresses breast cancer metastasis through downregulation of CD44.

Cun Zhang1, Yujin Xu1, Qiang Hao1, Shuning Wang1, Hong Li2, Jialin Li1, Yuan Gao1, Meng Li1, Weina Li1, Xiaochang Xue1, Shouzhen Wu1, Yingqi Zhang1, Wei Zhang1.   

Abstract

Forkhead box protein 3 (FOXP3) plays an important role in breast cancer as an X-linked tumor suppressor gene. However, the biological functions and significance of FOXP3 in breast cancer metastasis remain unclear. Here, we find that, clinically, nuclear FOXP3 expression is inversely correlated with breast cancer metastasis. Moreover, we demonstrate that FOXP3 significantly inhibits adhesion, invasion and metastasis of breast cancer cells in vivo and in vitro. In addition, the adhesion molecule CD44 is found to be suppressed by FOXP3 through transcriptome sequence analysis (RNA-seq). A luciferase reporter assay, chromatin immunoprecipitation and electrophoretic mobility shift assay identify CD44 as a direct target of FOXP3. The expression of CD44 is downregulated by FOXP3 in breast cancer cells. Importantly, anti-CD44 antibody reverses the FOXP3 siRNA-induced effects on the breast cancer cells in vitro and FOXP3 expression level in the nucleus of breast cancer cells is inversely correlated with CD44 expression level in clinic breast cancer tissues. Taken together, the results from the present study suggest that FOXP3 is a suppressor of breast cancer metastasis. FOXP3 directly binds to the promoter of CD44 and inhibits its protein expression, thereby suppressing adhesion and invasion of human breast cancer cells. This finding highlights the therapeutic potential of FOXP3-CD44 signaling to inhibit breast cancer metastasis.
© 2015 UICC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25683728     DOI: 10.1002/ijc.29482

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.

Authors:  Elena Sanmartín; Fernando Ortiz-Martínez; Eloy Pomares-Navarro; Araceli García-Martínez; Montserrat Rodrigo-Baños; Marta García-Escolano; Leire Andrés; Enrique Lerma; Francisco I Aranda; Pascual Martínez-Peinado; José M Sempere-Ortells; Gloria Peiró
Journal:  Virchows Arch       Date:  2016-11-24       Impact factor: 4.064

Review 2.  The role of CD44 in epithelial-mesenchymal transition and cancer development.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Hua Wu; Qian Liu; Richard G Pestell; Kongming Wu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

3.  Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas.

Authors:  Maria V Bogachek; Jung M Park; James P De Andrade; Allison W Lorenzen; Mikhail V Kulak; Jeffrey R White; Vivian W Gu; Vincent T Wu; Ronald J Weigel
Journal:  Stem Cell Reports       Date:  2016-12-01       Impact factor: 7.765

4.  FOXP3 inhibits cancer stem cell self-renewal via transcriptional repression of COX2 in colorectal cancer cells.

Authors:  Shuo Liu; Cun Zhang; Kuo Zhang; Yuan Gao; Zhaowei Wang; Xiaoju Li; Guang Cheng; Shuning Wang; Xiaochang Xue; Weina Li; Wei Zhang; Yingqi Zhang; Xianghui Xing; Meng Li; Qiang Hao
Journal:  Oncotarget       Date:  2017-07-04

5.  FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes.

Authors:  Bruna Karina Banin Hirata; Roberta Losi Guembarovski; Glauco Akelinghton Freire Vitiello; Alda Losi Guembarovski; Karen Brajão de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2017-06-21       Impact factor: 3.434

6.  RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes.

Authors:  María Sol Recouvreux; Esteban Nicolás Grasso; Pablo Christian Echeverria; Luciana Rocha-Viegas; Lucio Hernán Castilla; Carolina Schere-Levy; Johanna Melisa Tocci; Edith Claudia Kordon; Natalia Rubinstein
Journal:  Oncotarget       Date:  2016-02-09

7.  Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma.

Authors:  Jing-Jing Song; Si-Jia Zhao; Juan Fang; Da Ma; Xiang-Qi Liu; Xiao-Bing Chen; Yun Wang; Bin Cheng; Zhi Wang
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430

8.  CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.

Authors:  Ha Zhu; Yan Gu; Yiquan Xue; Ming Yuan; Xuetao Cao; Qiuyan Liu
Journal:  Oncotarget       Date:  2017-12-07

9.  Nuclear galectin-1-FOXP3 interaction dampens the tumor-suppressive properties of FOXP3 in breast cancer.

Authors:  Yuan Gao; Xiaoju Li; Zhen Shu; Kuo Zhang; Xiaochang Xue; Weina Li; Qiang Hao; Zhaowei Wang; Wangqian Zhang; Shuning Wang; Cheng Zeng; Dong Fan; Wei Zhang; Yingqi Zhang; Huadong Zhao; Meng Li; Cun Zhang
Journal:  Cell Death Dis       Date:  2018-04-01       Impact factor: 8.469

10.  FOXP3 Inhibits the Metastasis of Breast Cancer by Downregulating the Expression of MTA1.

Authors:  Chenlin Liu; Jun Han; Xiaoju Li; Tonglie Huang; Yuan Gao; Baolong Wang; Kuo Zhang; Shuning Wang; Wangqian Zhang; Weina Li; Qiang Hao; Meng Li; Yingqi Zhang; Cun Zhang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.